Clinical study of recombinant human interleukin-11 combined with ciclosporin in treatment of glucocorticoid invalid idiopathic thrombocytopenic purpura
10.3760/cma.j.issn.1673-4904.2012.25.010
- VernacularTitle:重组人白细胞介素-11联合环孢素治疗糖皮质激素无效的原发免疫性血小板减少症的临床研究
- Author:
Guizhen SUN
;
Beiping JIN
;
Xiaohong ZHANG
;
Haiyan ZHANG
;
Zhisheng LIU
- Publication Type:Journal Article
- Keywords:
Interleukin-11;
Cyclosporins;
Purpura,thrombocytopenic,idiopathic
- From:
Chinese Journal of Postgraduates of Medicine
2012;35(25):27-29
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo observe the effect of recombinant human interleukin-11 combined with ciclosporin in treatment of giucocorticoid invalid idiopathic thrombocytopenic purpura.MethodsFrom August 2009 to August 2011,35 cases with glucocorticoid invalid idiopathic thrombocytopenic purpura patients were divided into two groups according to the treatment method:13 cases in control group were treated with ciclosporin and 22 cases in observation group were treated with recombinant human interleukin-11 at basis of above method.The clinical effect and platelet counts between two groups were compared.Results The total effective rate in observation group was 90.9％ (20/22),which was significantly higher than that in control group [53.8％ (7/13)] (P ＜0.05).After treatment,the platelet counts in both two groups were significantly increased [control group:( 112.5 ± 15.4) × 109/t vs.(13.2 ± 1.8 ) × 109/L; observation group:( 132.7 ± 22.3 ) × 109/L vs.(12.9 ± 1.6) × 109/L] (P ＜ 0.05 ).Moreover,the platelet counts after treatment in observation group was significantly more than that in control group (P ＜ 0.05).ConclusionRecombinant human interleukin-11combined with ciclosporin in treatment of glucocorticoid invalid idiopathic thrombocytopenic purpura is a good treatment scheme,which can be applied in clinic.
